Cancer
Patient sample, cell culture and mouse studies suggest inhibiting β-catenin in combination with Xtandi enzalutamide could help treat prostate cancer. In tumor samples from prostate cancer patients, levels of β-catenin were higher in androgen deprivation therapy-resistant tumors than in sensitive tumors. In two human prostate cancer cell lines, an siRNA targeting β-catenin plus Xtandi decreased proliferation compared with either agent alone. In a xenograft mouse model of Xtandi-resistant prostate cancer and a patient-derived xenograft (PDX) mouse model of castration-resistant prostate cancer (CRPC), a tool compound β-catenin inhibitor plus Xtandi increased tumor cell apoptosis and decreased tumor volume and weight compared with either agent alone. Next steps could include testing additional β-catenin inhibitors in combination with Xtandi in models of prostate cancer.
Pfizer Inc. and Astellas Pharma Inc. market Xtandi, an androgen receptor antagonist, for prostate cancer...
BCIQ Company Profiles
BCIQ Target Profiles